Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS. Quality of life in adult and pediatric patients with tropomyosin receptor kinase fusion cancer receiving larotrectinib. Curr Probl Cancer. 2021 Dec;45(6):100734. doi: 10.1016/j.currproblcancer.2021.100734
Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Forns J, Esnaola M, Lopez-Vicente M, Suades-Gonzalez E, Alvarez-Pedrerol M, Julvez J, Grellier J, Sebastian-Galles N, Sunyer J. The n-back test and the attentional network task as measures of child neuropsychological development in epidemiological studies. Neuropsychology. 2014 Jul;28(4):519-29. doi: 10.1037/neu0000085
Lopez-Vicente M, Sunyer J, Forns J, Torrent M, Julvez J. Continuous Performance Test II outcomes in 11-year-old children with early ADHD symptoms: a longitudinal study. Neuropsychology. 2014 Mar;28(2):202-11. doi: 10.1037/neu0000048
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.